234 related articles for article (PubMed ID: 29096610)
1. Therapy response testing of breast cancer in a 3D high-throughput perfused microfluidic platform.
Lanz HL; Saleh A; Kramer B; Cairns J; Ng CP; Yu J; Trietsch SJ; Hankemeier T; Joore J; Vulto P; Weinshilboum R; Wang L
BMC Cancer; 2017 Nov; 17(1):709. PubMed ID: 29096610
[TBL] [Abstract][Full Text] [Related]
2. The expression of APE1 in triple-negative breast cancer and its effect on drug sensitivity of olaparib.
Chen T; Liu C; Lu H; Yin M; Shao C; Hu X; Wu J; Wang Y
Tumour Biol; 2017 Oct; 39(10):1010428317713390. PubMed ID: 29064327
[TBL] [Abstract][Full Text] [Related]
3. The Cisplatin, 5-fluorouracil, Irinotecan, and Gemcitabine Treatment in Resistant 2D and 3D Model Triple Negative Breast Cancer Cell Line: ABCG2 Expression Data.
Ata FK; Yalcin S
Anticancer Agents Med Chem; 2022; 22(2):371-377. PubMed ID: 34315389
[TBL] [Abstract][Full Text] [Related]
4. Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines.
Pierce A; McGowan PM; Cotter M; Mullooly M; O'Donovan N; Rani S; O'Driscoll L; Crown J; Duffy MJ
Cancer Biol Ther; 2013 Jun; 14(6):537-45. PubMed ID: 23760496
[TBL] [Abstract][Full Text] [Related]
5. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.
Chuang HC; Kapuriya N; Kulp SK; Chen CS; Shapiro CL
Breast Cancer Res Treat; 2012 Jul; 134(2):649-59. PubMed ID: 22678161
[TBL] [Abstract][Full Text] [Related]
6. miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer.
Tan X; Peng J; Fu Y; An S; Rezaei K; Tabbara S; Teal CB; Man YG; Brem RF; Fu SW
Breast Cancer Res; 2014 Sep; 16(5):435. PubMed ID: 25228385
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option.
Pessetto ZY; Yan Y; Bessho T; Natarajan A
Breast Cancer Res Treat; 2012 Jul; 134(2):511-7. PubMed ID: 22562176
[TBL] [Abstract][Full Text] [Related]
8. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
9. Multilayer architecture microfluidic network array for combinatorial drug testing on 3D-cultured cells.
Chang HC; Lin CH; Juang D; Wu HW; Lee CY; Chen C; Hsu CH
Biofabrication; 2019 Jun; 11(3):035024. PubMed ID: 31051482
[TBL] [Abstract][Full Text] [Related]
10. Differences in drug sensitivity between two-dimensional and three-dimensional culture systems in triple-negative breast cancer cell lines.
Muguruma M; Teraoka S; Miyahara K; Ueda A; Asaoka M; Okazaki M; Kawate T; Kuroda M; Miyagi Y; Ishikawa T
Biochem Biophys Res Commun; 2020 Dec; 533(3):268-274. PubMed ID: 32958246
[TBL] [Abstract][Full Text] [Related]
11. High-Throughput Microfluidic 3D Cytotoxicity Assay for Cancer Immunotherapy (CACI-IMPACT Platform).
Park D; Son K; Hwang Y; Ko J; Lee Y; Doh J; Jeon NL
Front Immunol; 2019; 10():1133. PubMed ID: 31191524
[TBL] [Abstract][Full Text] [Related]
12. Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine.
Nhukeaw T; Temboot P; Hansongnern K; Ratanaphan A
BMC Cancer; 2014 Feb; 14():73. PubMed ID: 24507701
[TBL] [Abstract][Full Text] [Related]
13. Influence of Matrices on 3D-Cultured Prostate Cancer Cells' Drug Response and Expression of Drug-Action Associated Proteins.
Edmondson R; Adcock AF; Yang L
PLoS One; 2016; 11(6):e0158116. PubMed ID: 27352049
[TBL] [Abstract][Full Text] [Related]
14. In vitro modeling of solid tumor interactions with perfused blood vessels.
Kwak TJ; Lee E
Sci Rep; 2020 Nov; 10(1):20142. PubMed ID: 33214583
[TBL] [Abstract][Full Text] [Related]
15. High-throughput 3D screening reveals differences in drug sensitivities between culture models of JIMT1 breast cancer cells.
Hongisto V; Jernström S; Fey V; Mpindi JP; Kleivi Sahlberg K; Kallioniemi O; Perälä M
PLoS One; 2013; 8(10):e77232. PubMed ID: 24194875
[TBL] [Abstract][Full Text] [Related]
16. Association of BRCA Mutations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell Lines.
Teraoka S; Muguruma M; Takano N; Miyahara K; Kawate T; Kaise H; Yamada K; Miyazawa K; Ishikawa T
J Surg Res; 2020 Jun; 250():200-208. PubMed ID: 32092597
[TBL] [Abstract][Full Text] [Related]
17. Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
Moustafa D; Elwahed MRA; Elsaid HH; Parvin JD
PLoS One; 2021; 16(1):e0235025. PubMed ID: 33412559
[TBL] [Abstract][Full Text] [Related]
18. Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.
Thike AA; Tan PH; Ikeda M; Iqbal J
Histopathology; 2016 Apr; 68(5):702-12. PubMed ID: 26259780
[TBL] [Abstract][Full Text] [Related]
19. Extracellular matrix enhances heregulin-dependent BRCA1 phosphorylation and suppresses BRCA1 expression through its C terminus.
Miralem T; Avraham HK
Mol Cell Biol; 2003 Jan; 23(2):579-93. PubMed ID: 12509456
[TBL] [Abstract][Full Text] [Related]
20. PARP inhibitor olaparib has a potential to increase the effectiveness of electrochemotherapy in BRCA1 mutated breast cancer in mice.
Bosnjak M; Jesenko T; Markelc B; Janzic L; Cemazar M; Sersa G
Bioelectrochemistry; 2021 Aug; 140():107832. PubMed ID: 33984694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
